Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 15%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

10x Genomics is a leading life science technology company, offering innovative solutions that analyze biological systems at a high resolution and scale. With a wide range of product offerings, including the Chromium platform and recent acquisitions such as Prime Mining, the company is in a strong position for growth in the coming years. In line with their history of strong financial performance and strategic investments, we project a positive outlook for 10x Genomics' stock.

Bears say

10x Genomics is facing risks to achieving their price target and recommendation, including competition from other companies in the market and the potential for their technology to become obsolete. Additionally, the company's success is heavily dependent on key customers and any disruptions in their supply chain could have a negative impact on their financial and operational results. These risks should be closely monitored and considered before making any investment decisions.

10X Genomics (TXG) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 15% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 13 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.